Topics

Clinical trials

Covid-19 Vaccine Study Results Could Come Late October, Moderna CEO Says - WSJ

Covid-19 Vaccine Study Results Could Come Late October, Moderna CEO Says

By: Peter Loftus
Source: The Wall Street Journal
Date of Publication: September 17th, 2020
Company also released the guidelines for the shot’s final-stage trial.
Pfizer says late-stage coronavirus vaccine study shows moderate side effects

Pfizer says late-stage coronavirus vaccine study shows moderate side effects

By: Manas Mishra
Source: Reuters
Date of Publication: September 15th, 2020
Pfizer Inc said on Tuesday participants were showing mild-to-moderate side effects when given either the company’s experimental coronavirus vaccine or a placebo in an ongoing late-stage study.
Vaccine makers pledge safety will be foremost - The Washington Post

Vaccine CEOs issue safety pledge amid Trump’s quest for pre-election approval

By: Christopher Rowland
Source: The Washington Post
Date of Publication: September 8th, 2020
Nine chief executives issued an extraordinary joint statement Tuesday seeking to bolster faith in coronavirus vaccine.
GSK, partner Vir join race to find COVID-19 antibody treatment

GSK, partner Vir join race to find COVID-19 antibody treatment

Source: Reuters
Date of Publication: August 31st, 2020
GlaxoSmithKline and partner Vir Biotechnology have started testing their experimental antibody on early-stage COVID-19 patients, entering the race to find a winner in a promising class of antiviral drugs to combat the pandemic.
Eli Lilly Studies Experimental Covid-19 Drug in Nursing Homes - WSJ

Eli Lilly Studies Experimental Covid-19 Drug in Nursing Homes

By: Peter Loftus
Source: The Wall Street Journal
Date of Publication: August 3rd, 2020
Late-stage trial explores whether antibody drug can help reduce infections in facilities with a diagnosed coronavirus case.
Sanofi, GlaxoSmithKline Ink Coronavirus Vaccine Deal With U.S. - WSJ

Sanofi, GlaxoSmithKline Ink Coronavirus Vaccine Deal With U.S.

By: Joseph Walker
Source: The Wall Street Journal
Date of Publication: July 31st, 2020
The deal, worth up to $2.1 billion and for 100 million doses, is the latest signed by the U.S. to secure supplies of Covid-19 vaccines.
The world’s biggest coronavirus vaccine study begins, a U.S. trial that will include 30,000 people to see if the shots really work

The world’s biggest coronavirus vaccine study begins, a U.S. trial that will include 30,000 people to see if the shots really work

Source: CNBC
Date of Publication: July 27th, 2020
The world’s biggest Covid-19 vaccine study got underway Monday with the first of 30,000 planned volunteers helping to test shots created by the U.S. government. There’s still no guarantee that the experimental vaccine, developed by the National Institutes of Health and Moderna, will really protect.
Moderna, Pfizer Coronavirus Vaccines Begin Final-Stage Testing - WSJ

Moderna, Pfizer Coronavirus Vaccines Begin Final-Stage Testing

By: Peter Loftus and Jared S. Hopkins
Source: The Wall Street Journal
Date of Publication: July 27th, 2020
Drugmakers to enroll 30,000 subjects across U.S., in separate trials to determine whether their vaccines prevent symptomatic Covid-19
Oxford University's coronavirus vaccine with AstraZeneca shows positive immune response in early trial

Coronavirus vaccine from Oxford and AstraZeneca shows positive response in early trial

By: Berkeley Lovelace Jr. and Lucy Handley
Source: CNBC
Date of Publication: July 20th, 2020
A potential coronavirus vaccine developed by Oxford University in the U.K. with pharmaceutical giant AstraZeneca has produced a promising immune response in a large, early-stage human trial.
Moderna spars with US scientists over COVID-19 vaccine trials

Exclusive: Moderna spars with U.S. scientists over COVID-19 vaccine trials

By: Marisa Taylor and Robin Respaut
Source: Reuters
Date of Publication: July 7th, 2020
As the United States accelerates the search for a coronavirus vaccine, tensions have erupted between government scientists and Moderna Inc, one of the leading developers, Reuters has learned.